As of March 31, 2026, EnBio Holdings, Inc. carries a market capitalization of 6.19B, placing it among publicly traded companies globally. Its enterprise value stands at 12.89B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.19B |
| Enterprise Value | 12.89B |
EnBio Holdings, Inc.'s next confirmed earnings release is scheduled for February 15, 2027.
| Earnings Date | 2/15/2027 |
As of March 31, 2026, EnBio Holdings, Inc. has 8.12M shares outstanding.
| Shares Outstanding | 8.12M |
These figures are as of March 31, 2026.
| PB Ratio | 0.67 |
| P/TBV Ratio | 0.70 |
As of March 31, 2026, EnBio Holdings, Inc. maintains a current ratio of 2.20, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.20 |
| Quick Ratio | 0.78 |
| Debt / Equity | 114.25 |
These figures cover the twelve months ended March 31, 2026.
| Employee Count | 104.00 |
As of the close on November 17, 2026, EnBio Holdings, Inc.'s stock has gained approximately 3.00% over the past 52 weeks. The 50-day moving average sits at 776.98, while the 200-day moving average is 757.00.
| 52-Week Price Change | 3.00% |
| 50-Day Moving Average | 776.98 |
| 200-Day Moving Average | 757.00 |
As of March 31, 2026, EnBio Holdings, Inc. holds 4.04B in cash and equivalents against 10.65B in total debt, resulting in a net debt position of 6.62B. Total book value stands at 9.25B, with working capital of 6.23B providing operational flexibility.
| Cash & Cash Equivalents | 4.04B |
| Total Debt | 10.65B |
| Net Debt | 6.62B |
| Equity (Book Value) | 9.25B |
| Book Value Per Share | 1,139.01 |
| Working Capital | 6.23B |
Already premium?